ClinicalTrials.gg
TerminatedNCT05461794Updated Jun 13, 2025Results posted

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

A Phase 2 interventional study of Sitravatinib and Tislelizumab in Esophageal Squamous Cell Carcinoma, sponsored by BeiGene. Terminated at 31 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-13.

Sponsored by BeiGene · Phase 2, Interventional, and Treatment

Why this study was terminated
Due to modification of company strategy.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma — 13 open to participants now, 15 under way, 1 of them phase 3. tislelizumab · Esophageal Squamous Cell Carcinoma.

Enrollment
7th of 23
96 · median 50
Started
2022
with 9 others
Phase 2
14 of 23
8 open now
Registered
10th of 23
by date
Lead sponsor
5 of 23
BeiGene

Among the 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma, this one is the 7th largest by enrollment, is one of 10 that started in 2022, is one of 14 in phase 2, and was the 10th registered.

Esophageal Squamous Cell Carcinoma

676 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

13 of the 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma are open now, in 4 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma, or all of them as a file.
02

Study summary

The study aimed to evaluate the efficacy and safety of sitravatinib in combination with tislelizumab as a second- or third-line treatment for participants with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma (ESCC) who experienced disease progression following prior systemic chemotherapy.

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma

Keywords

  • esophageal squamous cell carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. or cytologically confirmed locally advanced unresectable or ESCC, not amenable to treatment with curative intent
  2. At least 1 as defined per (RECIST) v1.1 as determined by local site investigator/radiology assessment ≤ 28 days before randomization Note: Lesions that had been previously irradiated were considered evaluable provided
  3. (ECOG) score ≤ 1
  4. Adequate organ function as indicated by the following laboratory values as indicated by the laboratory tests performed ≤ 7 days before randomization

Key Exclusion Criteria:

  1. Have any for receiving treatment with both docetaxel and irinotecan
  2. Participants with tumor located around important vascular structures as shown by imaging or the investigator determines that the tumor is likely to invade important blood vessels and may cause fatal bleeding (ie, radiologic evidence of tumors invading or abutting major blood vessels)
  3. Participants with tumor that invades into organs located adjacent to the esophageal disease site (eg, aorta or respiratory tract) that has an increased risk of fistula during the study treatment period as assessed by the investigator
  4. History of gastrointestinal perforation and/or fistula or aorto-esophageal fistula within 6 months before randomization
  5. Have received prior anticancer agents that have same mechanism of action as sitravatinib (eg, receptor tyrosine kinases (RTKs) with a similar target profile or Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor-targeted (VEGFR) monoclonal antibodies)

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    Arm A: Tislelizumab + Sitravatinib

    Sitravatinib administered orally and tislelizumab administered intravenously

    Drug: Sitravatinib · Drug: Tislelizumab

  • Experimental
    Arm B: Sitravatinib

    Sitravatinib administered orally

    Drug: Sitravatinib

  • Experimental
    Arm C: Investigator-chosen chemotherapy (ICC)

    Investigators chose between docetaxel or irinotecan

    Drug: Docetaxel · Drug: Irinotecan

Interventions

  • 100 mg orally once daily

    Also known as: BGB-9468

  • 200 mg intravenously once every 3 weeks

    Also known as: BGB-A317

  • 75 milligrams per square meter of body surface area (mg/m2) intravenously on Day 1 of every 21-day cycle

  • 125 mg/m2 intravenously on Days 1 and 8 of every 21-day cycle

06

What researchers measure

Primary outcomes

  1. Arms A and C: Overall Response Rate (ORR)

    ORR is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) as assessed by the investigator per the Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1.

    Time frame: Through study completion data cut-off date of February 26th, 2024 (maximum time on study was 12 months)

Secondary outcomes

  1. Duration of Response (DOR)

    Defined as the time from the first occurrence of a documented objective response to the time of documented disease progression assessed by the investigator or death from any cause, whichever occurred first, in all randomized participants with documented objective responses.

    Time frame: Through study completion data cut-off date of February 26th, 2024 (maximum time on study was 12 months)

  2. Overall Survival (OS)

    Defined as the time from randomization until the date of death due to any cause. Kaplan-Meier methodology was used to estimate the median OS.

    Time frame: Through study completion data cut-off date of February 26th, 2024 (maximum time on study was 12 months)

  3. Disease Control Rate (DCR)

    Defined as the percentage of participants whose best overall response is complete response, partial response, or stable disease, as assessed by the investigator per RECIST v1.1

    Time frame: Through study completion data cut-off date of February 26th, 2024 (maximum time on study was 12 months)

  4. Clinical Benefit Rate (CBR)

    Defined as the percentage of participants with a complete response, partial response, or durable stable disease (defined as stable disease for 24 weeks or longer, as assessed by the investigator per RECIST v.1.1.

    Time frame: Through study completion data cut-off date of February 26th, 2024 (maximum time on study was 12 months)

  5. Progression Free Survival (PFS)

    Defined as the time from randomization until first documentation of disease progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurred first. Kaplan-Meier methodology was used to estimate the median PFS.

    Time frame: Through study completion data cut-off date of February 26th, 2024 (maximum time on study was 12 months)

  6. Arms A and B: Overall Response Rate (ORR)

    ORR is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) as assessed by the investigator per RECIST v1.1. Analysis of ORR in Arm A compared to Arm B was specified as a secondary endpoint in the Protocol (please see the primary outcome measure for Arm C results)

    Time frame: Through study completion data cut-off date of February 26th, 2024 (maximum time on study was 12 months)

  7. Number of Participants With Adverse Events

    Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, and vital signs, according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0

    Time frame: From the first dose to 30 days after the last dose or the start of new anticancer therapy, whichever occurred first (maximum time on treatment was 8.9 months for Arm A, 7.7 months for Arm B, and 8.0 months for Arm C).

07

Results

Posted Jun 13, 2025
Limitations and caveats
Data and results should be interpreted with caution due to limited sample size and prematurity of data resulting from early termination and incomplete enrollment.

Participant flow

Participants were enrolled across multiple study centers in China. The first participant provided consent on October 3, 2022, and the last participant completed the study on February 26, 2024.

Participant flow — Overall Study
MilestoneArm A: Tislelizumab + SitravatinibArm B: SitravatinibArm C: Investigator-chosen Chemotherapy (ICC)
Started391938
Treated391934
Completed000
Not completed391938
Withdrew: Withdrawal by subject113
Withdrew: Study terminated by sponsor181316
Withdrew: Death20519

Outcome measures

PrimaryArms A and C: Overall Response Rate (ORR)

ORR is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) as assessed by the investigator per the Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1.

Time frame:
Through study completion data cut-off date of February 26th, 2024 (maximum time on study was 12 months)
Reported as:
Number · percentage of participants
Arms A and C: Overall Response Rate (ORR)
percentage of participantsArm A: Tislelizumab + SitravatinibArm C: Investigator-chosen Chemotherapy (ICC)
Arms A and C: Overall Response Rate (ORR)10.3 (2.9 to 24.2)5.3 (0.6 to 17.7)
Statistical analysis
  • Arm A: Tislelizumab + Sitravatinib vs Arm C: Investigator-chosen Chemotherapy (ICC) · Odds ratio (or): 2.1 · 95% CI 0.3 to 23.9The crude odds ratio was estimated along with exact unconditional 95% CIs constructed by the tail method based on the score statistics.
  • Arm A: Tislelizumab + Sitravatinib vs Arm C: Investigator-chosen Chemotherapy (ICC) · Risk difference (rd): 5.0 · 95% CI -9.3 to 19.5The risk difference was estimated along with their exact unconditional 95% CIs constructed by the tail method based on the score statistics.
SecondaryDuration of Response (DOR)

Defined as the time from the first occurrence of a documented objective response to the time of documented disease progression assessed by the investigator or death from any cause, whichever occurred first, in all randomized participants with documented objective responses.

Time frame:
Through study completion data cut-off date of February 26th, 2024 (maximum time on study was 12 months)
Reported as:
Median · months
Duration of Response (DOR)
monthsArm A: Tislelizumab + SitravatinibArm B: SitravatinibArm C: Investigator-chosen Chemotherapy (ICC)
Duration of Response (DOR)5.2 (4.4 to NA)4.6 (2.8 to NA)NA (2.8 to NA)
SecondaryOverall Survival (OS)

Defined as the time from randomization until the date of death due to any cause. Kaplan-Meier methodology was used to estimate the median OS.

Time frame:
Through study completion data cut-off date of February 26th, 2024 (maximum time on study was 12 months)
Reported as:
Median · months
Overall Survival (OS)
monthsArm A: Tislelizumab + SitravatinibArm B: SitravatinibArm C: Investigator-chosen Chemotherapy (ICC)
Overall Survival (OS)6.1 (3.4 to 7.5)9.1 (6.5 to NA)5.5 (4.7 to 6.6)
Statistical analysis
  • Arm A: Tislelizumab + Sitravatinib vs Arm C: Investigator-chosen Chemotherapy (ICC) · Hazard ratio (hr): 0.85 · 95% CI 0.45 to 1.61Hazard ratio and 95% CIs were estimated using a Cox regression model stratified by PD-L1 tumor area positivity score (\>=10% versus \< 10%)
SecondaryDisease Control Rate (DCR)

Defined as the percentage of participants whose best overall response is complete response, partial response, or stable disease, as assessed by the investigator per RECIST v1.1

Time frame:
Through study completion data cut-off date of February 26th, 2024 (maximum time on study was 12 months)
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsArm A: Tislelizumab + SitravatinibArm B: SitravatinibArm C: Investigator-chosen Chemotherapy (ICC)
Disease Control Rate (DCR)64.1 (47.2 to 78.8)63.2 (38.4 to 83.7)42.1 (26.3 to 59.2)
Statistical analysis
  • Arm A: Tislelizumab + Sitravatinib vs Arm C: Investigator-chosen Chemotherapy (ICC) · Odds ratio (or): 2.5 · 95% CI 0.9 to 6.8The crude odds ratio was estimated along with exact unconditional 95% CIs constructed by the tail method based on the score statistics
  • Arm A: Tislelizumab + Sitravatinib vs Arm B: Sitravatinib · Odds ratio (or): 1.0 · 95% CI 0.3 to 3.7The odds ratio was estimated along with their exact unconditional 95% CIs constructed by the tail method based on the score statistics.
  • Arm A: Tislelizumab + Sitravatinib vs Arm C: Investigator-chosen Chemotherapy (ICC) · Risk difference (rd): 22.0 · 95% CI -1.5 to 43.3The risk difference was estimated along with their exact unconditional 95% CIs constructed by the tail method based on the score statistics.
  • Arm A: Tislelizumab + Sitravatinib vs Arm B: Sitravatinib · Risk difference (rd): 0.9 · 95% CI -24.5 to 28.4The risk difference was estimated along with their exact unconditional 95% CIs constructed by the tail method based on the score statistics.
SecondaryClinical Benefit Rate (CBR)

Defined as the percentage of participants with a complete response, partial response, or durable stable disease (defined as stable disease for 24 weeks or longer, as assessed by the investigator per RECIST v.1.1.

Time frame:
Through study completion data cut-off date of February 26th, 2024 (maximum time on study was 12 months)
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR)
percentage of participantsArm A: Tislelizumab + SitravatinibArm B: SitravatinibArm C: Investigator-chosen Chemotherapy (ICC)
Clinical Benefit Rate (CBR)17.9 (7.5 to 33.5)26.3 (9.1 to 51.2)5.3 (0.6 to 17.7)
Statistical analysis
  • Arm A: Tislelizumab + Sitravatinib vs Arm C: Investigator-chosen Chemotherapy (ICC) · Odds ratio (or): 3.9 · 95% CI 0.7 to 40.8The crude odds ratio was estimated along with exact unconditional 95% CIs constructed by the tail method based on the score statistics.
  • Arm A: Tislelizumab + Sitravatinib vs Arm B: Sitravatinib · Odds ratio (or): 0.6 · 95% CI 0.1 to 2.9The odds ratio was estimated along with their exact unconditional 95% CIs constructed by the tail method based on the score statistics.
  • Arm A: Tislelizumab + Sitravatinib vs Arm C: Investigator-chosen Chemotherapy (ICC) · Risk difference (rd): 12.7 · 95% CI -2.3 to 29.5The risk difference was estimated along with their exact unconditional 95% CIs constructed by the tail method based on the score statistics.
  • Arm A: Tislelizumab + Sitravatinib vs Arm B: Sitravatinib · Risk difference (rd): -8.4 · 95% CI -34.7 to 13.8The risk difference was estimated along with their exact unconditional 95% CIs constructed by the tail method based on the score statistics.
SecondaryProgression Free Survival (PFS)

Defined as the time from randomization until first documentation of disease progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurred first. Kaplan-Meier methodology was used to estimate the median PFS.

Time frame:
Through study completion data cut-off date of February 26th, 2024 (maximum time on study was 12 months)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsArm A: Tislelizumab + SitravatinibArm B: SitravatinibArm C: Investigator-chosen Chemotherapy (ICC)
Progression Free Survival (PFS)3.4 (2.1 to 5.6)5.6 (2.1 to NA)2.6 (1.5 to 3.8)
Statistical analysis
  • Arm A: Tislelizumab + Sitravatinib vs Arm C: Investigator-chosen Chemotherapy (ICC) · Hazard ratio (hr): 0.53 · 95% CI 0.29 to 0.96Hazard ratio and 95% CIs were estimated using a Cox regression model stratified by the selected stratification factors PD-L1 tumor area positivity score (\>=10% versus \< 10%)
  • Arm A: Tislelizumab + Sitravatinib vs Arm B: Sitravatinib · Hazard ratio (hr): 1.96 · 95% CI 0.79 to 4.82Hazard ratio and 95% CIs were estimated using a Cox regression model stratified by the selected stratification factors PD-L1 tumor area positivity score (\>=10% versus \< 10%)
SecondaryArms A and B: Overall Response Rate (ORR)

ORR is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) as assessed by the investigator per RECIST v1.1. Analysis of ORR in Arm A compared to Arm B was specified as a secondary endpoint in the Protocol (please see the primary outcome measure for Arm C results)

Time frame:
Through study completion data cut-off date of February 26th, 2024 (maximum time on study was 12 months)
Reported as:
Number · percentage of participants
Arms A and B: Overall Response Rate (ORR)
percentage of participantsArm A: Tislelizumab + SitravatinibArm B: Sitravatinib
Arms A and B: Overall Response Rate (ORR)10.3 (2.9 to 24.2)21.1 (6.1 to 45.6)
Statistical analysis
  • Arm A: Tislelizumab + Sitravatinib vs Arm B: Sitravatinib · Odds ratio (or): 0.4 · 95% CI 0.1 to 2.7The crude odds ratio was estimated along with exact unconditional 95% CIs constructed by the tail method based on the score statistics
SecondaryNumber of Participants With Adverse Events

Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, and vital signs, according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0

Time frame:
From the first dose to 30 days after the last dose or the start of new anticancer therapy, whichever occurred first (maximum time on treatment was 8.9 months for Arm A, 7.7 months for Arm B, and 8.0 months for Arm C).
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsArm A: Tislelizumab + SitravatinibArm B: SitravatinibArm C: Investigator-chosen Chemotherapy (ICC)
TEAEs391934
SAEs22615

Adverse events

Collected over All-cause mortality was assessed through the end of study, February 26th, 2024 (maximum time on study was 12 months). Adverse events were assessed from the first dose of study drug to 30 days after the last dose or the start of new anticancer therapy, whichever occurred first (maximum time on treatment was 8.9 months for Arm A, 7.7 months for Arm B, and 8.0 months for Arm C).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Tislelizumab + Sitravatinib20/39 (51.3%)22/39 (56.4%)39/39 (100%)
Arm B: Sitravatinib5/19 (26.3%)6/19 (31.6%)19/19 (100%)
Arm C: Investigator-chosen Chemotherapy (ICC)19/38 (50%)15/34 (44.1%)34/34 (100%)
Most frequent serious events
Showing 10 of 66
Most frequent serious events
EventArm A: Tislelizumab + SitravatinibArm B: SitravatinibArm C: Investigator-chosen Chemotherapy (ICC)
DeathGeneral disorders5/390/192/34
Neutrophil count decreasedInvestigations0/390/193/34
White blood cell count decreasedInvestigations0/390/193/34
PneumoniaInfections and infestations3/391/192/34
Gastrointestinal haemorrhageGastrointestinal disorders0/391/190/34
Gastrooesophageal reflux diseaseGastrointestinal disorders0/391/191/34
Oesophageal obstructionGastrointestinal disorders0/391/191/34
Chest painGeneral disorders0/391/190/34
COVID-19 pneumoniaInfections and infestations2/391/191/34
Skin infectionInfections and infestations0/391/190/34
Most frequent other events
Showing 10 of 107
Most frequent other events
EventArm A: Tislelizumab + SitravatinibArm B: SitravatinibArm C: Investigator-chosen Chemotherapy (ICC)
White blood cell count decreasedInvestigations7/395/1924/34
Neutrophil count decreasedInvestigations3/395/1921/34
AnaemiaBlood and lymphatic system disorders12/395/1920/34
Aspartate aminotransferase increasedInvestigations15/399/192/34
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders9/398/190/34
DiarrhoeaGastrointestinal disorders5/393/1914/34
Platelet count decreasedInvestigations9/397/196/34
Weight decreasedInvestigations10/397/199/34
NauseaGastrointestinal disorders3/394/1912/34
Alanine aminotransferase increasedInvestigations13/396/194/34

Baseline characteristics

The Intent-to-Treat (ITT) analysis set included all randomized participants

Age, Continuous
Age, Continuous(years)Arm A: Tislelizumab + SitravatinibArm B: SitravatinibArm C: Investigator-chosen Chemotherapy (ICC)Total
Mean59.1 ± 7.7361.9 ± 7.8760.4 ± 8.0660.2 ± 7.87
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Tislelizumab + SitravatinibArm B: SitravatinibArm C: Investigator-chosen Chemotherapy (ICC)Total
Female2237
Male37173589
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm A: Tislelizumab + SitravatinibArm B: SitravatinibArm C: Investigator-chosen Chemotherapy (ICC)Total
Asian39193896
08

Study locations

31 sites
  • Anhui Provincial Hospital South Brance
    Hefei, Anhui 230036, China
  • Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital
    Hefei, Anhui 230088, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing 100050, China
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
  • Beijing Luhe Hospital, Capital Medical University
    Beijing, Beijing 101149, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350005, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
  • Sun Yat Sen University Cancer Center
    Guangzhou, Guangdong 510060, China
  • Sun Yat Sen University Cancer Center(Huangpu Campus)
    Guangzhou, Guangdong 510700, China
  • Cancer Hospital of Shantou University Medical College
    Shantou, Guangdong 515031, China
  • The Tumor Hospital Affiliated to Guangxi Medical University
    Nanning, Guangxi 530021, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • The First Affiliated Hospital of Xinxiang Medical University
    Xinxiang, Henan 453100, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Xiangyang Central Hospital
    Xiangyang, Hubei 441021, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • Northern Jiangsu Peoples Hospital
    Yangzhou, Jiangsu 225001, China
  • Ganzhou Peoples Hospital Ganzhou Hospital Affiliated to Nanchang University
    Ganzhou, Jiangxi 341000, China
  • The First Affiliated Hospital of Nanchang University Branch Donghu
    Nanchang, Jiangxi 330006, China
  • Jilin Cancer Hospital
    Changchun, Jilin 130021, China
  • Liaoning Cancer Hospital and Institute
    Shenyang, Liaoning 110042, China
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
  • Weifang Peoples Hospital
    Weifang, Shandong 261000, China
  • Rui Jin Hospital Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai 200025, China
  • Affiliated Zhongshan Hospital of Fudan University
    Shanghai, Shanghai 200032, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
    Chengdu, Sichuan 610071, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin 300052, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Feb 2024, 16 months.

Results were first posted in Jun 2025, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2022
First posted
Jul 18, 2022
StartActual
Oct 3, 2022
Primary completionActual
Feb 26, 2024
CompletionActual
Feb 26, 2024
Results first posted
Jun 13, 2025
Last update
Jun 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05461794
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Jul 18, 2022
Start date
Oct 3, 2022
Primary completion
Feb 26, 2024
Completion
Feb 26, 2024
Results posted
Jun 13, 2025
Last update
Jun 13, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sitravatinib · Tislelizumab · Docetaxel · Irinotecan

Start the discussion